Free Trial
NASDAQ:COCP

Cocrystal Pharma Q1 2025 Earnings Results & Report

Cocrystal Pharma logo
$1.07 0.00 (0.00%)
Closing price 10/9/2026 03:58 PM Eastern
Extended Trading
$1.08 +0.00 (+0.47%)
As of 10/9/2026 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cocrystal Pharma beat analyst earnings expectations in its Q1 2025 results, released May 15, 2025. The company reported EPS of -$0.23 versus the -$0.52 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens

Cocrystal Pharma EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.52
Beat/Miss
Beat by +$0.29
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Cocrystal Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Cocrystal Pharma's next earnings date is estimated for Friday, November 13, 2026, based on past reporting schedules.

Conference Call Resources

Cocrystal Pharma Q1 2025 Earnings FAQ

Cocrystal Pharma (NASDAQ:COCP) reported earnings of -$0.23 per share for Q1 2025, beating the consensus estimate of -$0.52. The report was announced on Thursday, May 15, 2025.

Cocrystal Pharma's next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for Cocrystal Pharma on the company's earnings history page.

Cocrystal Pharma Earnings Headlines

Brokers Set Expectations for COCP Q4 Earnings
Free Ticker: Anthropic's silent partner could soar after record $2 trillion IPO
Anthropic's IPO prospectus just leaked, revealing 261 pages tied to a record $2 trillion valuation. Beyond headline backers Amazon and Google, tech analyst Matt McCall has tracked a smaller partner that got in early, before most investors knew Claude existed. Matt calls it a Second IPO opportunity and reveals its name and ticker in a free interview.tc pixel
COCP: $5 Million Private Placement with OPKO Health
See More Cocrystal Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cocrystal Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cocrystal Pharma and other key companies, straight to your email.

About Cocrystal Pharma

Cocrystal Pharma (NASDAQ:COCP) is a clinical-stage biotechnology company focused on discovering and developing antiviral therapies. The company uses a structure-based drug discovery platform to identify small-molecule compounds designed to interfere with essential viral replication proteins.

Its research programs have targeted a range of viral diseases, including influenza A, norovirus and coronaviruses. Cocrystal’s development activities have included orally administered antiviral candidates intended for the treatment or prevention of viral infections, with programs advancing through a combination of preclinical research and clinical development.

Founded in 2007 and formerly known as BioZone Pharmaceuticals, the company adopted the Cocrystal Pharma name after combining with Cocrystal Discovery in 2015. Cocrystal is headquartered in Bothell, Washington, and its research and development efforts are directed primarily toward potential antiviral treatments for markets in the United States and internationally.

View Cocrystal Pharma Profile